PR Newswire - Phase II Data of Cadonilimab Regimen as Neoadjuvan...
HONG KONG, Dec. 9, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that data from the Phase II study (COMPASSION-25) for its first-in-class PD-1/CTLA-4 bispecific antib...
Read More

ภาษาไทย
English